Beximco Pharmaceuticals Ltd Beximco Pharma wins at Scrip Awards 2018

TIDMBXP

Beximco Pharmaceuticals Ltd

29 November 2018

29 November 2018

BEXIMCO PHARMACEUTICALS LTD.

Beximco Pharma wins Community Partnership of the Year at the 2018 Scrip Awards

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No. : 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the Company has won the award with DSM Nutritional Products (DSM) for 'Community Partnership of the Year' at the Scrip Awards, presented in London, England, on 28 November 2018.

The Community Partnership of the Year award recognises pharma and biotech companies for the way in which they contribute to the wider community. In this instance, Beximco Pharma and DSM have been commended for their work with the Center for Human Nutrition and the Sight & Life Global Nutrition Research Institute at the Johns Hopkins University Bloomberg School of Public Health and the JiVitA Maternal and Child Research Institute of the Johns Hopkins University, Bangladesh. The partnership has been dedicated to supporting community nutrition and health research that can lift the health burden of micronutrient deficiencies from women, infants and children in impoverished regions of rural Bangladesh and South Asia.

Beximco Pharma Managing Director, Mr Nazmul Hassan MP, commented:

"It is a huge honour to receive a prestigious Scrip Award and in particular to be recognised for our work within the community. Driven by shared values in public health and a commitment to contribute resources that can promote equity, we are working hand-in-hand with DSM and Johns Hopkins University to manufacture, bottle, test and deliver tens of millions of micronutrient supplements for the JiVitA Research Institute in NW Bangladesh. Ultimately, we hope this partnership will improve the health of each generation in rural Bangladesh and South Asia and we look forward to continuing to work with DSM and Johns Hopkins University to achieve this goal."

In its 14(th) year, the Scrip Awards programme recognises the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. The awards provide the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain and to recognise both corporate and individual achievement. A panel of 17 independent, senior industry experts judged the award entries to select the finalists.

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: [phone], ext.20080

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; [phone], [phone], Ext 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: [phone] / 3555

Northland Capital Partners Limited (Broker)

Vadim Alexandre / Dugald J. Carlean

Tel: [phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 4,200 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAPGGBGGUPRURB

(END) Dow Jones Newswires

November 29, 2018 03:30 ET (08:30 GMT)